• Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL's role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR
• Selective AXL inhibitor, bemcentinib, shown to reverse AXL's effects, thus acting synergistically with immune cells and anti-cancer therapies
• Data further strengthens broad development opportunities for bemcentinib both as a monotherapy, and in combinations, in a broad spectrum of cancers
PR Newswire
BERGEN, Norway, April 2, 2019